A new biomanufacturing partnership will boost Canada’s manufacturing capacity, projecting pandemic-induced revenue loss for Canada’s universities, IPIC makes pre-budget recommendations, and more.
Topic: Canadian biomanufacturing
Ottawa prepares for future pandemics with launch of life science strategy, CellCAN and CCRM launch a new cell and gene therapy institute to tackle gaps in training, a new fund dedicated to developing transit solutions for rural and remote communities, and more.
Minister Champagne announces construction of NRC’s vaccine plant in Montreal is complete, Concordia gets go-ahead for a new school of interdisciplinary health, NISC receives quantum research funding to improve online communication security, and more.
Resilience Biotechnologies receives significant funding to produce made-in-Canada vaccines, Ottawa extends the CAN Health Network project in Ontario by one year with a $3.25-million investment, Canada’s nuclear leaders collaborate on the decommissioning process, and more.
The federal government’s investment of $887 million make Canada self-sufficient in manufacturing vaccines against COVID-19 and future pandemics, say medical and other experts. Along with Canadian-led vaccine development, Ottawa is investing in a network of small-scale vaccine manufacturing facilities that together will be able to produce enough vaccine for Canada’s population during pandemics.